Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » SRS Medical wins FDA nod for expanded study of Spanner prostate stent

SRS Medical wins FDA nod for expanded study of Spanner prostate stent

By

SRS MedicalSRS Medical Systems said it won the FDA’s approval for a clinical trial of its Spanner prostate stent for an expanded indication, a temporary implant designed to replace indwelling and intermittent urinary catheters.

The Spanner device consists of a pair of anchors and a silicone tube and is designed to reduce resistance in the bladder neck and prostatic urethra without stenting the external sphincter, SRS said. It’s blind, anesthesia-free implantation procedure is similar to that for a Foley catheter, according to the company.

The FDA approved Spanner in October 2014 for a single, 30-day period in a limited number of patients, Billerica, Mass.-based SRS said. The new investigational device exemption from the federal safety watchdog is for a 103-patient study examining unrestricted, long-term use of the device in all patients who are not candidates for traditional prostate treatments, the company said.

“By replacing a urinary catheter with a prostate stent, care providers reduce the risk of urinary tract infection, improve patient quality-of-life, and decrease the factors which commonly contribute to higher overall healthcare costs, such as length-of-stay, readmissions and other catheter-related complications,” CEO Lee Brody said in prepared remarks. “We are delighted to have reached agreement with FDA and, based on our clinical experience with the Spanner, we are confident that we will achieve the clinical safety endpoints established in collaboration with FDA for this confirmatory study.”

“We have been using the Spanner for several years in a limited patient population,” added Dr. Shahin Tabatabaei of the Harvard Medical School and Mass. General Hospital. “Patients who receive this intra-urethral device instead of a urinary catheter have dramatically lower rates of urinary tract infection and greatly prefer the stent to a catheter. If the IDE study demonstrates long-term effectiveness in a wide patient population, the Spanner could replace urinary catheters as a standard of care in the management of some male patients with retention.”

In case you missed it

RSS From Medical Design & Outsourcing

  • Johnson & Johnson MedTech plans manufacturing facility in Costa Rica
    Johnson & Johnson MedTech will build a 200,000-sf² manufacturing facility in Alajuela, Costa Rica, the medical device developer said today. It’s the largest investment J&J MedTech has ever made outside the U.S., according to Procomer, the agency that promotes Costa Rican exports. J&J MedTech — Johnson & Johnson’s medical device business — said the plant… […]
  • The secret behind Intuitive’s surgical robotics success
    Intuitive Surgical has pioneered robotic surgery since the 1990s, continuously driving innovation and collaboration through data to advance patient care. Teamwork between surgeons and engineers has been a crucial factor behind Intuitive developing effective surgical platforms that solve real-world problems that surgeons face. Multibillion-dollar companies including Medtronic and Johnson & Johnson — and smaller up-and-comers… […]
  • 3D-printed ventricles made from fiber-infused gel ink mimic heartbeats
    Researchers have found a way to use fiber-infused ink to 3D-print a functional heart ventricle that mimics the beating of a human heart. The team included researchers from Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and the Wyss Institute for Biologically Inspired Engineering at Harvard University. They reported on their new… […]
  • Synchron’s plan to beat Neuralink in the neuroprosthetic BCI race
    Competing brain-computer interface (BCI) developers Synchron and Neuralink both announced big news this month as they move their dueling neuroimplant technologies forward. The device developers each have FDA investigational device exemption (IDE) for their experimental BCIs. They’ve also got billionaires backing their R&D and regulatory efforts, with Neuralink owned by Elon Musk and Synchron funded… […]
  • How LimFlow’s foot-saving system prevents amputations in patients with no other options
    LimFlow’s breakthrough system for treating chronic limb-threatening ischemia (CLTI) is the first of its kind approved by the FDA for this severe form of peripheral artery disease (PAD). For CLTI patients who have lost blood flow below their knee and have no other suitable endovascular or surgical treatment options available, the LimFlow System for Transcatheter… […]
  • Device strategies to prevent healthcare-associated infections
    Device design, sterilization before use and proper cleaning of reusable equipment can prevent infections and save lives. By Ted Eveleth, AvantGuard Nosocomial infections, also commonly known as healthcare-associated infections (HAIs), are a multibillion-dollar problem and a leading cause of morbidity and mortality around the world. On any given day, about 1 in 31 hospital patients… […]
  • MGS breaks ground on innovation and tech center
    MGS has started construction of its new innovation center at its headquarters campus in Germantown, Wisconsin. The medtech contract manufacturer said the 120,000 ft² facility is scheduled to open by the end of 2024. The MGS expansion will have collaborative workspaces dedicated to ideation and product development, tooling development, automation, and part and process validation,… […]
  • Two-armed surgical robot prototype targets pediatric brain tumors
    Researchers say they’ve developed a surgical robot for removing brain tumors in children, and that it could also offer a less invasive, safer option for adult neurosurgery and other procedures. The trick is using hollow, nitinol robot arms to allow neurosurgeons to swap tools during a tumor resection procedure, said Pierre DuPont. He’s the chief… […]
  • S3 Connected Health joins DiMe’s International Regulatory Pathways project
    NEWS RELEASE: S3 Connected Health joins DiMe’s team of digital health experts in their new project ‘International Regulatory Pathways’ DUBLIN, September 19, 2023 – Building on the success of the Digital Health US Regulatory Pathways, DiMe has assembled a global team of digital health experts, including S3 Connected Health, to support digital health product developers… […]
  • Four steps medtech startups can’t put off
    Developing and commercializing a new medical device is a success worth toasting for medtech startups — but that success also makes it more likely that litigation is in their future. There are steps medtech startups can take to protect themselves down the road, said Greenberg Traurig shareholder Ginger Pigott, a litigator who defends major medical… […]
  • How Biosense Webster aims to expand access to AFib care
    Electrophysiology is “an incredibly vibrant space,” said Nikki Sidi, but access remains a challenge. Nikki Sidi, the U.S. president of Johnson & Johnson’s Biosense Webster, can look at her own company as one of those paving the way in electrophysiology (EP). Its recent milestones include multiple atrial fibrillation (AFib) mapping catheters, including ablation and mapping devices. … […]

Copyright © 2023 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy